Atea Pharmaceuticals, Inc.

NASDAQ•AVIR

CEO: Dr. Jean-Pierre Sommadossi Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2020-10-30

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

連絡先情報

225 Franklin Street, Suite 2100, Boston, MA, 02110, United States

857-284-8891

ateapharma.com

時価総額

$488.39M

PER (TTM)

-3.0

17.2

配当利回り

52週高値

$6.45

52週安値

$2.46

52週レンジ

92%

順位45Top 56.8%

3.6

F-Score

改良版 Piotroski 分析

7年ファンダメンタル

弱い • 3.6 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2019-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.57+0.00%

直近4四半期の推移

フリーCF

-$28.22M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

HCV Phase 3 Trials Progressing C-BEYOND fully enrolled; C-FORWARD enrollment expected complete YE 2026; NDA targeted March 2027.

Net Loss Narrows Significantly Net loss decreased $10.0 M to $(158.3) M in 2025; R&D spend increased slightly to $148.0 M.

Cash Position Strong Cash, equivalents, and securities totaled $301.8 M on December 31, 2025, sufficient through 2027.

Workforce Reduction Completed 25% workforce reduction in Q1 2025 expected to yield $15.0 M aggregate cost savings through 2027.

リスク要因

High Dependence on HCV Candidate Business highly dependent on successful HCV regimen development, approval, and commercialization; failure causes significant harm.

Need Substantial Future Financing Expect substantial operating expenses; failure to obtain necessary capital could delay or terminate product development efforts.

Regulatory Approval Unpredictable Regulatory approval processes are lengthy, expensive, and inherently unpredictable; failure to obtain approval seriously harms business.

Intellectual Property Litigation Risk Facing patent challenges from Gilead Sciences regarding bemnifosbuvir; adverse ruling requires licensing or halts commercialization.

見通し

Targeting HCV NDA Submission Targeting submission of HCV regimen NDA to FDA in March 2027, pending successful completion of Phase 3 trials.

Initiate HEV Phase 1 Study Anticipate initiating clinical development of AT-587 for chronic HEV with a first-in-human Phase 1 study mid-2026.

Cash Funds Operations Through 2027 Current cash position of $301.8 M is expected to fund planned operations through the end of 2027.

Merck Milestone Payment Anticipated Next $10.0 M Merck milestone payment anticipated due upon acceptance of HCV regimen NDA in H1 2027.

同業比較

売上高 (TTM)

VNDA

$216.11M

+8.7%

ARCT

$74.12M

-46.4%

ENTA

$66.98M

+0.6%

粗利益率 (最新四半期)

ENTA

100.0%

+0.0pp

VNDA

93.3%

+0.1pp

FHTX

91.3%

-245.3pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
VTYX	$1.00B	-9.4	-48.1%	4.7%
OMER	$799.05M	-6.2	57.3%	103.2%
ALLO	$510.14M	-2.6	-57.1%	18.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月11日

EPS:-$0.56

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし